Company profile
MariMed Inc.
OTC: MRMD · Healthcare · Drug Manufacturers - Specialty & Generic
#305 of 1,418 Healthcare companies by revenue44th-percentile growth
EA Score
66BFH 63DQ 80GM 49SS 67
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ revenue growth (YoY), balance-sheet leverage
Methodology →Revenue TTM
$161.5M
Rev growth YoY (TTM)
+2.2%
Net income (FY)
-$14.5M
Employees
866
as of 2026-08-20
Market cap
$27.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$159.8M$159.8M2025
Net income-$14.5M-$14.5M2025
Operating income-$2.8M-$2.8M2025
Total assets$202.6M$202.6M2025
Liabilities$137.8M$137.8M2025
Equity$50.0M$50.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Sales56%
Product Sales - Wholesale44%
Other1%
By geography
Not disclosed.
The read
What is MariMed Inc.’s revenue?
MariMed Inc. booked $159.8M in FY2025 revenue, growing 1.2% year over year — about the middle of the pack among Healthcare companies we track, at a -9.1% net margin.
Peers · Healthcare
Ginkgo Bioworks Holdings, Inc.44DMaze Therapeutics, Inc.49DPacific Biosciences of California, Inc.55CLiquidia Corporation58CHeron Therapeutics, Inc.58CAirSculpt Technologies, Inc.58CNeighbors
Norfolk →Key facts
CEOJon R. Levine
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNorwood, MA
ExchangeOTC: MRMD
Employees866
IPO date2012-08-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.